ABUS Arbutus Biopharma Corporation Stock Quote

ABUS [NASD]

Index	-	P/E	-	EPS (ttm)	-1.00	Insider Own	1.40%	Shs Outstand	86.31M	Perf Week	-6.97%
Market Cap	308.29M	Forward P/E	-	EPS next Y	-0.67	Insider Trans	-4.09%	Shs Float	63.55M	Perf Month	-17.25%
Income	-75.90M	PEG	-	EPS next Q	-0.23	Inst Own	25.40%	Short Float	6.51%	Perf Quarter	-23.82%
Sales	6.90M	P/S	44.68	EPS this Y	65.40%	Inst Trans	-7.10%	Short Ratio	1.76	Perf Half Y	-2.85%
Book/sh	-0.55	P/B	-	EPS next Y	22.10%	ROA	-64.80%	Target Price	-	Perf Year	155.83%
Cash/sh	1.23	P/C	2.50	EPS next 5Y	-	ROE	125.90%	52W Range	1.02 - 9.02	Perf YTD	-13.52%
Dividend	-	P/FCF	-	EPS past 5Y	6.20%	ROI	122.00%	52W High	-65.96%	Beta	2.89
Dividend %	-	Quick Ratio	13.40	Sales past 5Y	-21.60%	Gross Margin	-	52W Low	200.98%	ATR	0.21
Employees	78	Current Ratio	13.40	Sales Q/Q	50.00%	Oper. Margin	-	RSI (14)	38.38	Volatility	7.01% 5.86%
Optionable	Yes	Debt/Eq	-	EPS Q/Q	50.00%	Profit Margin	-	Rel Volume	0.84	Prev Close	3.20
Shortable	Yes	LT Debt/Eq	-	Earnings	Mar 04 BMO	Payout	-	Avg Volume	2.35M	Price	3.07
Recom	2.10	SMA20	-8.08%	SMA50	-17.58%	SMA200	-10.85%	Volume	1,989,292	Change	-4.06%

Feb-25-21

Initiated

Jefferies

Hold

Dec-17-20

Initiated

H.C. Wainwright

Buy

$10

Jul-27-20

Resumed

JMP Securities

Mkt Outperform

$10 → $8

Jul-24-20

Downgrade

Robert W. Baird

Outperform → Neutral

May-19-20

Upgrade

Wedbush

Neutral → Outperform

Mar-06-20

Upgrade

Chardan Capital Markets

Neutral → Buy

Feb-20-20

Initiated

Robert W. Baird

Outperform

Feb-05-20

Upgrade

JMP Securities

Mkt Perform → Mkt Outperform

$10

Oct-07-19

Reiterated

B. Riley FBR

Buy

$7 → $3

Oct-04-19

Downgrade

Chardan Capital Markets

Buy → Neutral

Oct-16-18

Upgrade

B. Riley FBR

Neutral → Buy

$11.50 → $9

Oct-15-18

Upgrade

Wedbush

Underperform → Neutral

Oct-12-18

Reiterated

Chardan Capital Markets

Buy

$12 → $6.50

Jul-06-18

Downgrade

B. Riley FBR, Inc.

Buy → Neutral

$9 → $9

Mar-19-18

Resumed

Chardan Capital Markets

Buy

$8.25

Mar-19-18

Downgrade

Wedbush

Outperform → Neutral

$9 → $6

Jan-05-18

Initiated

B. Riley FBR, Inc.

Buy

$10

Apr-04-17

Upgrade

Chardan Capital Markets

Neutral → Buy

$3 → $6

Feb-01-17

Reiterated

Wedbush

Outperform

$13 → $10

Dec-13-16

Downgrade

Chardan Capital Markets

Buy → Neutral

$4 → $3

Apr-16-21 01:21AM	Introducing Arbutus Biopharma (NASDAQ:ABUS), The Stock That Zoomed 167% In The Last Year Simply Wall St.
Mar-17-21 08:58AM	Arbutus Gets Go Ahead To Kick Off Phase 1a/1b Clinical Trial Of AB-836 SmarterAnalyst
Mar-16-21 07:30AM	Arbutus Receives Regulatory Approval to Initiate a Phase 1a/1b Clinical Trial with AB-836, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Infection GlobeNewswire
Mar-04-21 10:01PM	Arbutus Biopharma (ABUS) Q4 2020 Earnings Call Transcript Motley Fool -13.74%
08:55AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates Zacks
08:10AM	Recap: Arbutus Biopharma Q4 Earnings Benzinga
07:30AM	Arbutus Reports Fourth Quarter and Year End 2020 Financial Results and Provides Corporate Update GlobeNewswire
06:45AM	Arbutus Biopharma Corp. to Host Earnings Call ACCESSWIRE
Mar-03-21 10:42AM	Earnings Preview: Arbutus Biopharma Benzinga
08:38AM	Is a Surprise Coming for Arbutus Biopharma (ABUS) This Earnings Season? Zacks
Mar-02-21 08:00AM	Arbutus to Participate at H.C. Wainwright Global Life Sciences Conference GlobeNewswire
Feb-26-21 11:52AM	Assembly Bio/Arbutus Bio Start Testing Vebicorvir/AB-729 Triplet Therapy In HBV Infection Benzinga
07:30AM	Assembly Biosciences and Arbutus Biopharma Initiate Phase 2 Clinical Trial of Triple Combination Therapy for the Treatment of Chronic Hepatitis B Virus GlobeNewswire
Feb-22-21 08:00AM	Arbutus to Report Fourth Quarter and Year End 2020 Financial Results and Provide Corporate Update GlobeNewswire
Feb-14-21 11:14PM	Here's What Arbutus Biopharma Corporation's (NASDAQ:ABUS) Shareholder Ownership Structure Looks Like Simply Wall St.
Jan-25-21 07:30AM	Arbutus Announces 2021 Corporate Objectives and Provides Financial Update GlobeNewswire
Jan-04-21 08:00AM	Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright BioConnect 2021 Conference GlobeNewswire
Dec-31-20 11:11PM	Are Investors Undervaluing Arbutus Biopharma Corporation (NASDAQ:ABUS) By 26%? Simply Wall St.
Dec-15-20 08:52AM	Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options Zacks
Dec-14-20 09:18AM	Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options Zacks +24.81%
Dec-12-20 04:02PM	Is ABUS A Good Stock To Buy Now? Insider Monkey
Dec-10-20 07:30AM	Arbutus Announces Robust HBsAg Decline Data with AB-729 Dosed at 60 mg Every 8 Weeks in Chronic Hepatitis B Subjects GlobeNewswire +7.62%
Nov-16-20 07:00AM	Arbutus Announces Additional Robust HBsAg Decline Data with AB-729 in Chronic Hepatitis B Subjects GlobeNewswire
Nov-15-20 02:40PM	Arbutus Announces Presentation of Phase 1a/1b Clinical Trial Results for AB-729 in Chronic Hepatitis B Subjects at The Liver Meeting Digital Experience, The American Association for the Study of Liver Diseases Meeting GlobeNewswire
Nov-12-20 08:32AM	Implied Volatility Surging for Arbutus Biopharma (ABUS) Stock Options Zacks
Nov-10-20 08:00AM	Arbutus to Present at Jefferies Virtual London Healthcare Conference GlobeNewswire
Nov-07-20 07:06AM	Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Are Cutting Their Estimates: Here's What You Need To Know Simply Wall St.
Nov-05-20 09:25AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks -6.21%
07:30AM	Arbutus Reports Third Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Nov-04-20 09:21AM	Return On Capital Employed Overview: Arbutus Biopharma Benzinga +5.88%
Oct-28-20 12:32PM	Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
Oct-16-20 06:01AM	We're Keeping An Eye On Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-13-20 08:00AM	Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright Hepatitis B Virus (HBV) Mini-Conference GlobeNewswire
Sep-28-20 08:00AM	Arbutus to Participate in Virtual Fireside Chat at Chardans 4th Annual Genetic Medicines Conference GlobeNewswire
Sep-15-20 07:30AM	Arbutus Announces AB-729 90 mg Single-Dose Week 12 Data in Chronic Hepatitis B Subjects Demonstrating Significant and Continuous Reductions in HBsAg GlobeNewswire +12.21%
Sep-09-20 08:00AM	Arbutus to Participate in Virtual Fireside Chat at H.C. Wainwright 22nd Annual Global Investment Conference GlobeNewswire
Aug-27-20 08:00AM	Assembly Biosciences and Arbutus Biopharma Announce Clinical Collaboration Agreement to Evaluate the Combination of Core Inhibitor ABI-H0731 with RNAi Therapeutic AB-729 in Patients with Chronic Hepatitis B Virus Infection GlobeNewswire
Aug-26-20 08:40AM	Are Options Traders Betting on a Big Move in Arbutus Biopharma (ABUS) Stock? Zacks
Aug-17-20 08:59AM	The Arbutus Biopharma (NASDAQ:ABUS) Share Price Is Up 136% And Shareholders Are Boasting About It Simply Wall St.
Aug-12-20 11:27AM	ROCE Insights For Arbutus Biopharma Benzinga
Aug-10-20 11:30AM	Is Arbutus Biopharma (ABUS) Outperforming Other Medical Stocks This Year? Zacks
Aug-07-20 08:55AM	Arbutus Biopharma (ABUS) Reports Q2 Loss, Lags Revenue Estimates Zacks -13.04%
07:50AM	Recap: Arbutus Biopharma Q2 Earnings Benzinga
07:30AM	Arbutus Reports Second Quarter 2020 Financial Results and Provides Corporate Update GlobeNewswire
Aug-05-20 08:00AM	Arbutus to Present at Wedbush PacGrow Healthcare Virtual Conference GlobeNewswire +11.47%
Jul-31-20 12:30PM	Will Arbutus Biopharma (ABUS) Report Negative Earnings Next Week? What You Should Know Zacks -11.40%
Jul-29-20 06:00PM	1 Reason to Sell Moderna Now Motley Fool
08:00AM	Arbutus to Report Second Quarter 2020 Financial Results GlobeNewswire
Jul-27-20 12:31PM	Will Arbutus Biopharma (ABUS) Report Negative Q2 Earnings? What You Should Know Zacks -9.98%
Jul-24-20 11:52PM	Moderna says patent ruling not to affect COVID-19 vaccine development Reuters -20.00%
03:31PM	Moderna Lost a Patent Case and the Stock Is Slipping Barrons.com
12:57PM	Tiny Arbutus Biopharma Wins Patent Litigation Fight with COVID-19 Vaccine Implications Motley Fool
11:25AM	How Moderna's Patent Challenge Loss Could Impact Coronavirus Vaccine Program Benzinga
08:59AM	Moderna's stock falls the day after 'disappointing' patent ruling MarketWatch
07:15AM	The Daily Biotech Pulse: Mixed Tidings From Novavax, Radius Health Out-licenses Breast Cancer Drug, 3 IPOs Benzinga
12:38AM	Moderna loses challenge to Arbutus patent on vaccine technology Reuters
12:02AM	Moderna Faces Hurdle With Coronavirus Vaccine As Court Refuses To Invalidate Arbutus Patent Benzinga
Jul-23-20 05:39PM	Moderna Dives On Patent Battle That Could Jeopardize Coronavirus Vaccine Investor's Business Daily +119.86%
Jun-15-20 08:18PM	Is Arbutus Biopharma Corp (ABUS) A Good Stock To Buy? Insider Monkey +6.36%
May-27-20 08:00AM	Arbutus to Present at Jefferies Virtual Healthcare Conference GlobeNewswire
May-20-20 01:18PM	Biotech Stock Roundup: MRNA, DVAX Up on Coronavirus Treatment Updates, & More Zacks
May-19-20 11:11AM	P/E Ratio Insights for Arbutus Biopharma Benzinga +23.53%
May-18-20 04:05PM	Arbutus Announces Single-Dose Week 12 Data in Chronic Hepatitis B Subjects with 60 mg AB-729 Demonstrating a Significant and Continuous Reduction in HBsAg GlobeNewswire -10.95%
06:05AM	Forecast: Analysts Think Arbutus Biopharma Corporation's (NASDAQ:ABUS) Business Prospects Have Improved Drastically Simply Wall St.
May-15-20 11:04AM	Why Arbutus (ABUS) Stock Might be a Great Pick Zacks +14.13%
09:15AM	Arbutus' Shares March Higher, Can It Continue? Zacks
May-14-20 02:22PM	3 Strong Buy Penny Stocks With Triple-Digit Upside TipRanks +8.24%
May-12-20 08:00AM	Arbutus to Present at UBS Virtual Global Healthcare Conference GlobeNewswire +14.58%
May-11-20 11:19AM	Moving Average Crossover Alert: Arbutus Biopharma Zacks +6.67%
07:45AM	Arbutus Biopharma (ABUS) Reports Q1 Loss, Misses Revenue Estimates Zacks
07:12AM	Arbutus Biopharma: Q1 Earnings Insights Benzinga
06:00AM	Arbutus Reports First Quarter 2020 Financial Results, Provides Pipeline Update and Announces New Research Initiative to Identify Novel Antiviral Therapies for the Treatment of Coronavirus Infections GlobeNewswire
May-04-20 08:00AM	Arbutus to Report First Quarter 2020 Financial Results GlobeNewswire +13.08%
Apr-27-20 12:32PM	Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know Zacks
Mar-31-20 08:47AM	Do Options Traders Know Something About Arbutus Biopharma (ABUS) Stock We Don't? Zacks -9.82%
06:16AM	The Arbutus Biopharma Corporation (NASDAQ:ABUS) Analysts Have Been Trimming Their Sales Forecasts Simply Wall St.
Mar-27-20 08:02AM	The Daily Biotech Pulse: Sanofi-Translate Bio Join Hands For Coronavirus Vaccine, TherapeuticsMD Suspends Guidance Benzinga -46.46%
Mar-26-20 04:05PM	Arbutus Announces Positive Preliminary Phase 1a/1b Clinical Trial Results for AB-729, a Proprietary GalNAc Delivered RNAi Compound in Development for People Living with Chronic Hepatitis B GlobeNewswire +5.12%
Mar-05-20 08:55AM	Arbutus Biopharma (ABUS) Reports Q4 Loss, Tops Revenue Estimates Zacks
07:30AM	Arbutus Reports Fourth Quarter and Year End 2019 Financial Results, Confirms 2020 Corporate Objectives and Provides Pipeline Update GlobeNewswire
Feb-27-20 12:30PM	Arbutus Biopharma (ABUS) May Report Negative Earnings: Know the Trend Ahead of Q4 Release Zacks +10.71%
08:00AM	Arbutus to Report Fourth Quarter and Year-End 2019 Financial Results GlobeNewswire
Feb-10-20 08:00AM	Arbutus Announces Decision to Discontinue AB-452 and to Pursue Development of a Next Generation HBV Specific Oral RNA-Destabilizer GlobeNewswire
Jan-02-20 05:05AM	Does The Arbutus Biopharma Corporation (NASDAQ:ABUS) Share Price Tend To Follow The Market? Simply Wall St. +5.76%
Dec-30-19 10:08AM	Options Traders Expect Huge Moves in Arbutus Biopharma (ABUS) Stock Zacks +9.64%
Dec-27-19 09:04AM	Spring Bank (SBPH) Stops Dosing in HBV Studies, Stock Down Zacks
Dec-19-19 03:50PM	Arbutus Biopharma Corp (ABUS): Hedge Funds In Wait-and-See Mode Insider Monkey
Nov-06-19 09:35AM	Arbutus Biopharma (ABUS) Reports Q3 Loss, Lags Revenue Estimates Zacks
07:30AM	Arbutus Reports Third Quarter 2019 Financial Results and Provides Corporate Update GlobeNewswire
Nov-03-19 07:13AM	We're A Little Worried About Arbutus Biopharma's (NASDAQ:ABUS) Cash Burn Rate Simply Wall St.
Oct-30-19 10:33AM	Will Arbutus Biopharma (ABUS) Report Negative Q3 Earnings? What You Should Know Zacks
07:30AM	Arbutus to Report Third Quarter 2019 Financial Results GlobeNewswire
Oct-10-19 02:59PM	Bucks biopharm firm halts study of potential hepatitis B cure American City Business Journals
Oct-04-19 07:32AM	The Daily Biotech Pulse: Arbutus Halts Hepatitis B Study, Positive Readout For MEI Pharma's Blood Cancer Drug, Ovid Offering Benzinga -28.67%
Oct-03-19 04:05PM	Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B Globenewswire Test
04:05PM	Arbutus Announces Decision to Discontinue Development of AB-506, an Oral Capsid Inhibitor for the Treatment of Chronic Hepatitis B GlobeNewswire
Sep-26-19 07:30AM	Arbutus to Participate in Upcoming Investor Conferences GlobeNewswire -6.25%
Sep-19-19 06:17AM	Did You Manage To Avoid Arbutus Biopharma's (NASDAQ:ABUS) Devastating 93% Share Price Drop? Simply Wall St.
Aug-20-19 04:05PM	Arbutus Biopharma Appoints Andrew Cheng, M.D., Ph.D., to its Board of Directors GlobeNewswire
Aug-06-19 07:30AM	Arbutus to Participate at Wedbush PacGrow Healthcare Conference GlobeNewswire

Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNA interference product candidate, which in an ongoing Phase Ia/Ib clinical trial targeted to hepatocytes that inhibits viral replication and reduces various HBV antigens using novel covalently conjugated GalNAc delivery technology; and AB-836, an oral capsid inhibitor that suppresses HBV DNA replication. The company's research and development programs include HBV RNA destabilizers, an orally active agent to destabilize HBV RNA, which leads to RNA degradation and to reduction in HBV proteins; oral PD-L1 inhibitor to enable reawakening patients' HBV-specific immune response; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Alnylam Pharmaceuticals, Inc. and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
McElhaugh Michael J.	Chief Business Officer	Feb 09	Sale	5.00	20,000	100,000	1,307,457	Feb 10 05:06 PM
McElhaugh Michael J.	Chief Business Officer	Dec 14	Sale	5.00	40,000	200,032	1,327,457	Dec 16 04:33 PM
McElhaugh Michael J.	Chief Business Officer	Jul 23	Sale	5.01	20,000	100,200	1,367,457	Jul 27 05:27 PM

open in yahoo | open in reuters | open in marketwatch | open in google

Upgrade your FINVIZ experience